First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo.
Eur J Med Chem. 2021 Jan 1;209:112903. doi: 10.1016/j.ejmech.2020.112903. Epub 2020 Oct 9.
Eur J Med Chem. 2021.
PMID: 33256948